A2 Biotherapeutics Stock
A2 Biotherapeutics develops novel medicines for serious illness.
Sign up today and learn more about A2 Biotherapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About A2 Biotherapeutics Stock
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
Funding History
| November 2019 | $57.0M |
|---|---|
| October 2020 | $71.5M |
Management
Sr Director Technology
Han Xu
Independent Director
Madhavan Balachandran
Vice President, Head of Technical Operations
Michelle Kreke
Vice President Operations
David Lucas
Senior Director Drug Discovery
Agi Hamburger
President and CSO
Alexander Kamb
Press
businesswire - Apr, 7 2024
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancerbusinesswire - Mar, 27 2024
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsendpts - Dec, 19 2022
Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapiesendpts - Oct, 7 2020
A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipelinegoo - Oct, 7 2020
A2 Biotherapeutics Closes $71.5M Series B FundingEquityZen Recognized As:
